Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: GlobeNewswire
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. “We enter 2026 with a clear focus on execution, building on the significant progress achieved across our development portf
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics (TNGX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Tango Therapeutics GAAP EPS of -$0.29 beats by $0.03, revenue of $0M misses by $0.5M [Seeking Alpha]Seeking Alpha
- Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics (NASDAQ:TNGX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $19.00 price target on the stock.MarketBeat
TNGX
Earnings
- 3/5/26 - Beat
TNGX
Sec Filings
- 3/5/26 - Form 144
- 3/5/26 - Form S-8
- 3/5/26 - Form 8-K
- TNGX's page on the SEC website